Figure 5.

Simvastatin improved the proportion and regulatory function of Tregs in PBMCs from ACS patients. (A) Representative FACS analysis of percentage CD4⁺CD25⁺Foxp3⁺ Tregs to total CD4⁺ cells in the control group. (B) Representative FACS analysis of percentage CD4⁺CD25⁺Foxp3⁺ Tregs to total CD4⁺ cells in 1 μmol/L simvastatin group. (C) Representative FACS analysis of percentage CD4⁺CD25⁺Foxp3⁺ Tregs to total CD4⁺ cells in the 10 μmol/L simvastatin group. (D) FACS analysis results: percentage CD4⁺CD25⁺Foxp3⁺ Tregs to total CD4⁺ cells in three groups of PBMCs. (E) Purified Tregs and CD4⁺CD25⁻ cells from PBMCs were incubated at different ratios (Tregs:CD4⁺CD25⁻ cells = 1:1, 1:2, 1:4, 1:8) without (control) or with simvastatin. [³H]-thymidine was added and proliferation was evaluated. *P < 0.05 versus control group. ^#P < 0.05 versus 1 μmol/L simvastatin group.